Sensei, Phase 2 Clinical Trial of Sapanisertib, an mTOR Inhibitor Targeting mTOR Mutations, Expected to Complete by the End of 2026
MATCH Subprotocol L as Part of a Precision Medicine Basket Trial
The MATCH clinical trial, led by the U.S. National Cancer Institute (NCI), includes Subprotocol L (EAY131-L), which evaluates the efficacy of sapanisertib in 35 patients with advanced refractory solid tumors harboring mTOR genetic mutations. Patient enrollment began in March 2017, and the trial is currently active, aiming for a primary completion date of December 31, 2026. The trial is garnering industry attention as it seeks to validate the potential of precision medicine by targeting specific gene mutations, regardless of the cancer's origin.
Mechanism of Action and Differentiation of Dual mTOR Inhibitor Sapanisertib
Sapanisertib (MLN0128/TAK-228) is a dual mTOR inhibitor that competitively binds to ATP and simultaneously blocks both TORC1 and TORC2. It is designed to overcome the limitations of first-generation rapalogs, such as everolimus, which only inhibit TORC1, leading to AKT feedback activation and the development of resistance. By simultaneously inhibiting mTORC1 and mTORC2, sapanisertib is expected to completely block the survival and proliferation signaling pathways of cancer cells, maximizing its anti-tumor effect.
Journey from License Sale and Bankruptcy to Final Acquisition
Originally developed by Takeda Pharmaceutical (TAK), the rights to this compound were licensed to Calithera Biosciences in October 2021 for an upfront payment of $45 million. However, Calithera filed for bankruptcy in early 2023, and the rights to sapanisertib were transferred to Faeth Therapeutics. Finally, in February 2026, Sensei Biotherapeutics (SNSE) acquired Faeth in an all-stock transaction, securing the final rights. Through this complex series of mergers and acquisitions (M&A), sapanisertib has now become a key asset in Sensei's pipeline.
Evolution into Combination Therapy 'PIKTOR' and Market Prospects
Sensei Biotherapeutics is not only developing sapanisertib as a single agent but is also expanding its development into the PIKTOR pipeline, a combination therapy that combines sapanisertib with serabelisib, a PI3K-alpha inhibitor. The company has initiated Phase 1b/2 clinical trials in breast cancer (HR+/HER2-) and Phase 2 trials in endometrial cancer, targeting the PI3K/AKT/mTOR signaling pathway-mutated cancer market, which represents a significant unmet need with a global market exceeding $5 billion annually. If the Phase 2 clinical trial demonstrates the single-agent efficacy of sapanisertib, the clinical validity and commercial value of the combination therapy will likely increase significantly.
This Phase 2 clinical trial of the MATCH Subprotocol L is a crucial milestone for demonstrating the single-agent efficacy of sapanisertib in targeting mTOR mutations, as evidenced by objective response rate (ORR) and progression-free survival (PFS) data. Originally developed by Takeda, then Calithera, and finally transferred to Sensei Biotherapeutics (SNSE) in February 2026, this compound is a key asset targeting the $5 billion PI3K/AKT/mTOR-mutated cancer market. In the short term, the data resulting from the clinical trial, scheduled for completion on December 31, 2026, is expected to serve as a catalyst for Sensei Biotherapeutics' stock momentum and pipeline value. In the medium to long term, by demonstrating superior safety and efficacy compared to existing competitive drugs such as Novartis' PI3K inhibitor Alpelisib, it will increase the probability of clinical success for Sensei's serabelisib combination therapy 'PIKTOR' and solidify its position in the precision cancer treatment market.
Source: ClinicalTrials.gov (api_ct)